NEUROTERA highlighted on Compete 2020's newsletter

13 September, 2018

Large newsletter

NEUROTERA: Development of innovative drugs against ocular and cerebral co-morbidities associated to Familial Amyloid Polyneuropathy (TTR-FAP).

This project aims at the development of therapeutic drugs to increase survival and improve the quality of life of patients with hereditary transthyretin amyloidosis and its co-morbidities. Another goal of the project is to contribute to reducing costs with treatments supported by health services and families, through providing more effective therapies.

Read more here

By continuing to browse the site, you expressly agree that cookies will be stored on your computer to help measure statistics of visits and improve the quality of the contents offered.Learn more